Developability refers to the likelihood that an antibody candidate will become a
manufacturable, safe and efficacious drug. Although the safety and efficacy of a drug …

Free-cysteine residues in recombinant biotherapeutics such as monoclonal antibodies can
arise from incorrect cellular processing of disulfide bonds during synthesis or by reduction of …

We studied unpaired cysteine levels and disulfide bond susceptibility in four different γ-
immunoglobulin antibodies using liquid chromatography–mass spectrometry. Our choice of …

CD24Fc is a homodimeric recombinant Fc-fusion protein comprised of human CD24
connected to immunoglobulin G1 (IgG1) Fc fragment. CD24 is heavily glycosylated, and its …

Studies of structural changes in mAbs under forced stress and storage conditions are
essential for the recognition of degradation hotspots, which can be further remodeled to …

Cysteine residues are crucial for the formation of conserved disulfide bonds in therapeutic
monoclonal antibodies (mAbs), which are essential for their folding and structural stability …

Abstract Development of monoclonal and bispecific antibody-based protein therapeutics
requires detailed characterization of native disulfide linkages, which is commonly achieved …

抗体类药物往往存在复杂多样的翻译后修饰(post-translational modifications, PTMs),
由此产生高度的异质性. PTMs 表征是抗体类药物研发的重要组成部分. 尤其在早期研发阶段 …